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The aim of this study was to determine whether N-methyl-2-pyrrolidone (NMP) can decrease the dose of recombinant human bone
morphogenetic protein-2 (rhBMP-2) in sinus augmentation of rabbits. In each of 15 rabbits, 2 sinuses were randomly grafted using 1
of 3 treatmentmodalities: (i) biphasic calcium phosphate (BCP; control), (ii) rhBMP-2-coated BCP (BMP), or (iii) rhBMP-2-coated
BCP soaked in NMP solution (BMP/NMP).The rabbits were sacrificed 2 weeks postoperatively. Histologic and histomorphometric
analyses were performed. Bone formation in all groups was predominantly located close to the access window and the lateral walls.
Newly formed bone within the total augmented area (NBTA) was greatest in BMP/NMP (1.94 ± 0.69mm
2), followed by BMP
(1.50 ± 0.72mm2) and BCP (1.28 ± 0.52mm2) (𝑃 > 0.05). In the center of the augmentation (NBROI_C) and the area close to the
sinus membrane (NBROI_M), BMP/NMP produced the largest area of NB (NBROI_C: 0.10 ± 0.11mm
2; NBROI_M: 0.17 ± 0.08mm
2);
the corresponding NB values for BCP were 0.05 ± 0.05mm2 and 0.08 ± 0.09mm2, respectively (𝑃 > 0.05 for all comparisons). The
effect of NMP on bone regeneration was inconsistent between the specimens. Adding NMP as an adjunct to rhBMP-2-coated BCP
produced inconsistent effects on bone regeneration, resulting in no significant benefit compared to controls.
1. Introduction
The challenges in implant dentistry include accomplishing
predictable regenerative outcomes in severely damaged or
atrophied sites within a short healing period. Conventional
approaches often require a relatively high level of surgical
skill to produce successful outcomes and are associated with
increased patientmorbidity [1].The introduction of recombi-
nant human bone morphogenetic protein-2 (rhBMP-2) was
considered revolutionary in both fulfilling clinical needs and
overcoming shortcomings of traditional procedures. Numer-
ous preclinical studies have found that the use of rhBMP-2
induced exceptional bone regenerationwithin a short healing
period [2–6]. Unfortunately, the use of rhBMP-2 is restricted
to few indications (only maxillary sinus augmentation and
extraction socket), due to its relatively high cost and potential
complications such as extensive postoperative swelling and
seroma formation [7, 8].
One possible way to limit these disadvantages is to
reduce the amount of rhBMP-2 needed for the surgical
intervention. One approach to consider is the simultaneous
use of an agent—a so-called enhancer—that boosts the bone-
regenerative effect. An ideal enhancer would increase the
rhBMP-2 bioactivity, have no detrimental effects, be easy
to apply clinically, and be inexpensive. Only a few studies
have evaluated such enhancers [9–12]. In a preclinical study,
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N-methyl-2-pyrrolidone (NMP) was used to increase the
flexibility of a barrier membrane [11]. Even though NMP
was originally used as a plasticizer, enhanced bone regen-
eration was observed in rabbit calvarial defects. In further
experiments, NMP treatment increased alkaline phosphatase
activity and calcium deposition in the presence of rhBMP-2
at a lower-than-usual dose [10]. At the molecular level, NMP
enhanced the kinase activity of the bone morphogenetic
protein (BMP) receptor type I homodimer, which led to
increases in Smad and p38 phosphorylation.Moreover, it was
demonstrated that NMP inhibited osteoclast differentiation
and function by blocking RANKL-induced AP-1 activation
[13].
When rhBMP-2 is used for bone augmentation, the
quantity of rhBMP-2 applied increases in proportion to the
carrier material used to fill the defect area [14]. Consid-
ering that sinus augmentation requires a large amount of
bone substitute material, overdosing of rhBMP-2 and high
treatment costs are likely. Thus, the combined use of an
enhancer and rhBMP-2 might offer several advantages for
sinus augmentation procedures.
The aim of the present study was to determine whether
or not NMP can decrease the dose of rhBMP-2 needed for
localized bone regeneration in a rabbit sinus augmentation
model.
2. Materials and Methods
2.1. Animals. Fifteenmale New ZealandWhite rabbits (Doo-
Yeol Biotech, Seoul, Korea) weighing 2.5∼3.0 kg were used in
this study. Each animal was housed in its own cage under
standard laboratory conditions.The animals were fed a pellet
diet and had access to water ad libitum. The experiment
was approved by the Institutional Animal Care and Use
Committee of Yonsei Medical Center, Seoul, Korea (IACUC
Approval number 2014-0364), and it was carried out between
March 2014 and November 2014.
2.2. Preparation of Materials. The following materials were
used for sinus augmentation: biphasic calcium phosphate
consisting of 30% hydroxyapatite and 70% ß-tricalcium
phosphate (BCP; Bio-C, Cowellmedi, Busan, Korea), rhBMP-
2 (Cowell BMP, Cowellmedi), and NMP (Sigma-Aldrich,
St. Louis, MO, USA). These materials were combined in
three treatment modalities for the experiment: BCP, BMP
(rhBMP-2-coated BCP), and BMP/NMP (rhBMP-2-coated
BCP soaked with NMP). RhBMP-2-coated BCP was pro-
duced as described earlier [15, 16]. Briefly, 0.025mg of
rhBMP-2 solution produced by Escherichia coli was mixed
with 1 g of the BCP granules and lyophilized. The mixture
was frozen on shelves at a temperature of –43∘C for 3 hours,
primarily dried in a condenser at –40∘C, and then placed
in a pressure chamber (5mmHg) for 2 hours. Secondary
drying was carried out by applying the following series at
5mmHg: –20∘C for 4 hours, –10∘C for 4 hours, 0∘C for 2
hours, and 20∘C for 20 hours. For the BMP/NMP group,
rhBMP-2-coated BCP particles were soaked in 0.2mL of
NMP (50 𝜇L/mL) for 5 minutes.
2.3. Surgical Intervention. Ketamine hydrochloride (Ketalar,
Yuhan, Seoul, Korea) and xylazine (Rumpun, Bayer Korea,
Seoul, Korea)were injected intramuscularly to induce general
anesthesia. The surgical site was shaved and locally disin-
fected. Local anesthesia was induced using 2% lidocaine
(lidocaine HCl, Huons, Seoul, Korea). Two experienced
surgeons (Ui-Won Jung and Hyun-Chang Lim) performed
the experimental surgery. A full-thickness flap was elevated
after making a mid-sagittal incision over the nasal area.
A circular reamer with a diameter of 5.5mm (C-reamer,
Neobiotech, Seoul, Korea) was used to access the sinus cavity
under irrigation. The sinus bone wall was detached and the
Schneiderian membrane was carefully elevated. Each sinus
was then assigned to one of the following three modalities
according to a computer-generated randomization list:
(1) BMP/NMP (rhBMP-2-coated BCP particles soaked
in NMP)
(2) BMP (rhBMP-2-coated BCP particles)
(3) BCP (BCP particles soaked in saline)
The amount of BCP used was 0.15 g in all groups. After
sinus augmentation, the flap was sutured with 6-0 glyconate
absorbable monofilament (Monosyn, B. Braun, Aesculap,
PA, USA). Postoperative medication with 0.5mg/kg ketoro-
lac (Keromin, Hana Pharm, Seoul, Korea) and 5mg/kg
enrofloxacin (Baytril, Bayer Korea) was administered twice
daily for 5 days postoperatively. All animals were sacrificed at
2 weeks after surgery using an overdose of anesthetic.
2.4. Histologic and Histomorphometric Analyses. The block
sections were immersed in 5% formic acid for 14 days and
then trimmed and embedded in paraffin. Coronal 5 𝜇m
thick sections were made serially along the center of the
window. The two central sections were stained with Mas-
son’s trichrome and hematoxylin-eosin. The specimens were
examined using a binocular microscope (Leica DMLB, Leica
Microsystems, Wetzlar, Germany). All images were captured
and saved (cellSens Standard 1.11, Olympus Corporation,
Center Valley, PA, USA) for histomorphometric evaluation.
Descriptive histology was performed by analyzing the
pattern of new bone (NB) formation, bone substitute degra-
dation, and potentially adverse healing events. Histomorpho-
metric measurement was performed in duplicate at 2-week
intervals by a masked, experienced examiner (Hyun-Chang
Lim) using an image processing program (Photoshop CS6,
Adobe Systems, San Jose, CA, USA). The total augmented
area (TA) encompassed a region bounded by the access win-
dow, the lateral sinus walls, and the Schneiderian membrane.
Within the TA, the area of new bone (NB) and the areas of
residual graft material (RM), and the area of nonmineralized
tissue (NM) were calculated. Moreover, three rectangular
regions of interest (ROIs) (1.1mm × 1.9mm) were designated
within the sinus: close to the access window (W), in the center
(C), and near the Schneiderian membrane (M) [17, 18]. NB,
RM, and NM were calculated in these three ROIs (Figure 1).
2.4.1. Primary Outcome
(i) NB within TA (NBTA).
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Figure 1: Histologic measurements of the augmented sinus. The
total augmentation was defined as the area surrounded by the
access window (arrowhead), lateral and medial sinus walls, and the
Schneiderian membrane (SM). Three rectangular ROIs (1.1mm ×
1.9mm) were established along the long axis of the augmentation:
close to the access window (W), in the center (C), and near the
Schneiderian membrane (M).
2.4.2. Secondary Outcomes
(i) RM and TA within TA (RMTA and NMTA, resp.).
(ii) NB, RM, and NM within the ROIs close to the bony
window (W) and in the center (C) and membrane
(M) regions (indicated using the subscripts “ROI_W”,
“ROI_C”, and “ROI_M”, resp.).
2.5. Statistical Analysis. For sample size calculation, each
sinus was regarded as a separate statistical unit. It was
assumed that (i) the amount of NB formation expected for
the control group (BCP) and the lower dose of rhBMP-2
(BMP) would be similar and that (ii) the addition of NMP
to rhBMP-2 (BMP/NMP) would result in a larger amount
of NB compared to BMP. The expected amount of NB was
determined based on the findings of a previous study [3]. In
order to achieve a power of 80% at an alpha level of 0.05, the
calculated sample size required for the present study was 10
sinuses per group, and so 30 sinuses (from 15 rabbits) were
prepared.
Histomorphometric data are presented as mean ± SD
values, with each sinus serving as an individual statistical
unit. The Shapiro-Wilk test was used to check that the data
conformed to a normal distribution.One-wayANOVAor the
Kruskal-Wallis test was used to assess statistical differences
among three groups. Pairwise post hoc comparisons between
BMP/NMP and BCP and between BMP and BCP were
performed using Dunnett’s test or the Mann–Whitney 𝑈 test
with Bonferroni correction (𝑃 = 0.05/2; SPSS 21.0, SPSS,
Chicago, IL, USA). The cutoff for statistical significance was
set at 𝑃 < 0.05.
3. Results
3.1. Clinical Findings. Therewere no cases of sinusmembrane
perforation during the surgical interventions. Postoperative
clinical healing was uneventful in all experimental animals,
Table 1: Histomorphometric analysis in total augmentation (mean
± SD; mm2).
BCP (𝑛 = 10) BMP (𝑛 = 10) BMP/NMP (𝑛 = 10)
TA 16.01 ± 3.01 19.07 ± 4.42 20.05 ± 4.51
NBTA 1.28 ± 0.52 1.50 ± 0.72 1.94 ± 0.69
RMTA 6.69 ± 1.43 6.92 ± 1.35 6.87 ± 1.28
NMTA 8.04 ± 1.71 10.66 ± 3.72 11.24 ± 4.07
No statistical difference among groups (𝑃 > 0.05); TA, total augmented area;
NBTA, new bone area within TA; RMTA, residual graft material area within
TA; NMTA, nonmineralized tissue area within TA.
and no subsequent complications were observed during the
healing period.
3.2. Descriptive Histology. Partially inflated balloon-shaped
augmentation was observed in all groups. The augmented
area was surrounded by newly formed bone (NB) starting
from the margins of the bony window, the lateral sinus walls,
and the Schneiderian membrane. Bone substitute particles
were observed within the entire augmented sinus and were
partially surrounded by NB. Angiogenesis was observed
throughout the specimens. Small blood vessels were observed
even in the center of the augmented area (Figure 2).
The amount of NB formation in the center of the
augmented sinus and in proximity to the Schneiderian
membrane appeared to be greater in BMP/NMP than in BMP
and BCP. Bone formation occurred predominantly near to
native bone walls (i.e., bony window and lateral walls) in
all groups. The residual graft material (RM) became more
shattered in some of the NMP/BMP and BMP specimens.
However, overall there was no remarkable difference in
healing among the three groups.Moreover, all groups showed
some variation in NB formation. Figure 2 shows histologic
specimens representing the least bone formation (Figures
3(a)–3(d)) and greatest bone formation (Figures 3(e)–3(h))
in BMP/NMP.
3.3. Histomorphometric Analysis. All of the data obtained in
the histomorphometric analysis are presented in Tables 1 and
2.
3.3.1. Analysis within the Total Augmented Area. Newly
formed bone area (NBTA) was greatest for BMP/NMP (1.94±
0.69mm2), followed by BMP (1.50 ± 0.72mm2) and BCP
(1.28 ± 0.52mm2). Similar trends were found for TA (20.05 ±
4.51mm2 for BMP/NMP, 19.07 ± 4.42mm2 for BMP, and
16.01 ± 3.01mm2 for BCP), RMTA, and NMTA. There was no
statistical difference in any of the above parameters among
the three groups (𝑃 > 0.05).
Each measured value for TA, NB, RM, and NM demon-
strated in the scattered plot that there was a large overlapping
zone for the values among the three groups, indicating large
variations between the specimens (Figure 4). This might
explain why none of the statistical intergroup comparisons
revealed any significant differences (see also Figure 2).
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Figure 2: Histologic observations in the experimental groups (Masson’s trichrome stain). ((a)–(c)) Overall views of the augmented sinus
(original magnification, ×20). ((d)–(l)) High-magnification views of the boxed areas in panels (a)–(c) in each group (original magnification,
×200). Arrowheads, new bone; asterisks, residual bone material.
Table 2: Histomorphometric analysis in the regions of interest
(ROI, mean ± SD; mm2).
BCP (𝑛 = 10) BMP (𝑛 = 10) BMP/NMP(𝑛 = 10)
NBROI_
W 0.25 ± 0.17 0.18 ± 0.19 0.22 ± 0.12
C 0.05 ± 0.05 0.08 ± 0.11 0.10 ± 0.11
M 0.08 ± 0.09 0.08 ± 0.07 0.17 ± 0.08
RMROI_
W 0.37 ± 0.23 0.55 ± 0.20 0.49 ± 0.19
C 1.22 ± 0.14 0.68 ± 0.33∗ 0.95 ± 0.20∗
M 1.00 ± 0.16 0.79 ± 0.25∗ 0.75 ± 0.15∗
NMROI_
W 1.45 ± 0.20 1.46 ± 0.19 1.44 ± 0.19
C 0.94 ± 0.17 1.44 ± 0.36∗ 1.15 ± 0.24
M 0.77 ± 0.18 0.92 ± 0.27 0.93 ± 0.20
∗Statistically significant compared to BCP; for intergroup comparisons of
NBROI_C and _M, RMROI_C, and NMROI_W and _C, Kruskal-Wallis test and
post hoc Mann–Whitney test using Bonferroni correction (𝑃 < 0.05/2)
were used. For the rest of intergroup comparisons, one-way ANOVA with
post hoc Dunnett’s test was used (𝑃 < 0.05); W, the region adjacent to
bony window; C, the center of the augmentation; M, the region adjacent
to Schneiderian membrane; NB, new bone area; RM, residual graft material
area; NM, nonmineralized tissue area.
3.3.2. Analyses within Regions of Interest. Close to the
bony window (W), the differences in newly formed bone
(NBROI_W) were small among the three treatment modalities
(ranging from 0.18 ± 0.19mm2 to 0.25 ± 0.17mm2). The
area of NB in the center (C) and membrane (M) regions
was larger for BMP/NMP than for BMP and BCP. The area
of NB within the C and M ROIs (NBROI_C and NBROI_M)
was 0.10 ± 0.11mm2 and 0.17 ± 0.08mm2, respectively, for
BMP/NMP; the corresponding values were 0.08 ± 0.11mm2
and 0.08 ± 0.07mm2 for BMP and 0.05 ± 0.05mm2 and
0.08 ± 0.09mm2 for BCP (𝑃 > 0.05 for all comparisons)
(Figure 5).
In W regions, the amount of bone substitute particles
(RMROI_W) was minimal, ranging from 0.37 ± 0.23mm
2 to
0.49 ± 0.19mm2, and there were no significant differences
between the three groups (𝑃 > 0.05). RMROI_C (1.22 ±
0.14mm2) and RMROI_M (1.00±0.16mm
2) were significantly
larger for BCP than for BMP/NMP (0.95 ± 0.20mm2 and
𝑃 = 0.005, and 0.75 ± 0.15mm2 and 𝑃 = 0.014, resp.) and
BMP (0.68 ± 0.33mm2 and 𝑃 < 0.001, and 0.79 ± 0.25mm2
and 𝑃 = 0.035).
The area of nonmineralized tissue (NM) was smallest in
the ROI close to the Schneiderian membrane in all groups.
NMROI_C was statistically larger for BMP than for BCP (𝑃 <
0.001).There were no other significant intergroup differences
in NMROIs (𝑃 > 0.05).
4. Discussion
The present study investigated the effect of NMP as an
enhancer for rhBMP-2 in a rabbit sinus augmentationmodel.
It was found that (i) adding NMP to rhBMP-2 resulted in
the largest area of newly formed bone within the entire
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Figure 3: Histologic comparisons showing the least and greatest bone regeneration in the BMP/NMP group (Masson’s trichrome stain). ((a),
(e)) Overall views of the augmented sinus (original magnification, ×20). ((b), (f)) High-magnification views of the window region (original
magnification, ×100). ((c), (g)) High-magnification views of the center region (original magnification, ×100). ((d), (h)) High-magnification
view of the membrane region (original magnification, ×100). Arrowheads, new bone; asterisks, residual bone material.
augmented sinus and the greatest bone formation, even
in regions further away from the access window, and (ii)
there were large variations between the specimens, which
was probably responsible for no significant differences being
found between the treatment modalities.
Factors limiting the use of rhBMP-2 include its relatively
high cost and postsurgical complications, which increase in
proportion to the dose of rhBMP-2 that is applied to the
defect. It was previously demonstrated that a small dose
of rhBMP-2 significantly enhanced mineral deposition and
the expression of bone formation markers in vitro when
used together with NMP [11]. Moreover, the enhancement
increased as the dose of rhBMP-2 was reduced, which sug-
gests that a bone-regenerative effect could be maintained by
decreasing the rhBMP-2 doses.This approach could therefore
be expected to providemore predictable regeneration of large
bone defects.
To date, few in vivo studies have tested the use of NMP
for localized bone regeneration [11, 19], especially when using
low-dose rhBMP-2 [10]. In calvarial defects of critical size
in rabbits, it was demonstrated that the addition of NMP
enhanced an ineffective rhBMP-2 dose (12𝜇g), leading to
significant bone regeneration compared to a control scaffold
[10]. In the present study, a smaller dose (3.75 𝜇g) was applied
to each sinus. This dose can be regarded as insufficient
for bone regeneration in a rabbit sinus on the basis of
previous results [16]. Following 2 weeks of healing after
sinus augmentation, newly formed bone within the total
augmented area (NBTA) was largest for BMP/NMP (1.5-fold
larger than for BCP) and larger in the regions having a lower
bone-regenerative potential (i.e., those in the center of the
augmented sinus and close to the Schneiderian membrane)
compared to other groups (twofold larger than for BCP).
However, the increase in NB with the application of NMP,
whether overall or in specific regions, did not reach statistical
significance.
The data obtained in this pilot study imply that the
addition of NMP to rhBMP-2 at an ineffective low dosemight
not predictably enhance bone regeneration. The average
amount of newly formed bone in the BMP/NMP group
appeared to be larger than in the control, but the degree of
enhancement was inconsistent between the specimens.These
outcomesmight be explained by (i) large variations in healing
characteristics between individual animals and (ii) the use of
a suboptimal delivery system.
In the course of bone healing following rhBMP-2 delivery,
in situ BMPs might act concomitantly with the exoge-
nous rhBMP-2. While the amount of exogenous rhBMP-2
could have been equal in each sinus in the present study,
the levels of in situ BMPs might vary between individual
animals and sinuses. Considering that the effect of NMP
might be proportional to the overall amount of BMP-2
from both sources, individual differences could be crucial
when analyzing the effect of a low dose of exogenously
delivered rhBMP-2. However, the variations in individual
healing cannot be controlled. Ideally, the effect of bioactive
agents should overcome individual differences and result in
bone regeneration being consistently effective above a certain
level. It has previously been reported that the individual
healing potential might not be greatly influenced by applying
NMP to a defect that is smaller than a critical size [11].
However, in the present study, larger defects (i.e., those in the
sinus cavity) appeared to be affected to a greater extent by
the individual healing potential. Specifically, large deviation
in new bone formation of BCP clearly represented that
individual healing was different (see Figure 4).This deviation
was also demonstrated in BMP/NMP, and some specimens in
BMP/NMP showed less new bone formation than BCP even
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Figure 4: Comparisons of tissue components in the entire augmented sinus. (a) Bar graph. ((b)–(e)) Scatter plots of the area of total
augmentation (TA), new bone (NB), residual material (RM), and nonmineralized tissue (NM), respectively.
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Figure 5: Findings of histomorphometric analyses in the regions of interest (ROIs). ((a)–(c)) Comparisons of the areas of new bone (NB),
residual graft material (RM), and nonmineralized tissue (NM) in each region, respectively. Asterisks indicate statistical differences compared
to the corresponding region for BCP.
though no surgical error and complication occurred. Such
findings can be translated that the combination of low dose
rhBMP-2 and NMP was not fully sufficient to enhance new
bone formation especially in the animal having relatively low
regenerative potential.
NMP is a water- and solvent-soluble molecule of low
weight, which makes it difficult to deliver in a controlled
and slow manner [10]. NMP incorporated in the membrane
starts to be released immediately after being placed at the
surgical site, and the membrane becomes stiff again [19].
Moreover, NMP is cleared from the body within a few hours
[20, 21]. Similarly, a slow delivery system for NMP may be
required for rhBMP-2 delivery. Alternatively, the periodic
injection of NMP can also be considered because NMP
is an injectable pharmaceutical excipient in FDA-approved
formulations. A weekly injection of NMP was previously
shown to produce antiosteoporotic activity in ovariectomized
rats [22, 23]. However, those authors stated that the frequency
and duration of the injections need be investigated further.
5. Conclusions
Using NMP as an adjunct to rhBMP-2-coated BCP increased
bone regeneration in the augmented sinus cavity, specifically
in the center of the augmentation and the region close
to the Schneiderian membrane. However, the effects were
inconsistent and did not result in significant differences
compared to bone substitute alone. The individual healing
potential may influence the effect of NMP, and so future
studies should attempt to obtain consistent findings for bone
regeneration.
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